Valuation: Positron Corporation

Market Cap 59.45M 51M 47.62M 43.69M 82.16M 5.68B 83.51M 562M 220M 2.85B 223M 218M 9.42B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 58.31M 50.02M 46.71M 42.85M 80.59M 5.57B 81.91M 551M 216M 2.8B 219M 214M 9.24B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
1 day-1.66%
1 week-1.66%
Current month+1.02%
1 month+4.09%
3 months-2.79%
6 months-18.35%
Current year+6.59%
1 week 1.67
Extreme 1.67
1.88
1 month 1.45
Extreme 1.45
1.88
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 27/02/2018
Sales & Marketing - 24/06/2022
Corporate Officer/Principal 40 25/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.66%-1.66%-3.78%+36.92% 59.45M
-0.48%-2.20%-16.20%-17.20% 13.28B
-3.96%+3.09%+24.86%+11.86% 4.66B
-1.58%-2.63%-41.68%-52.26% 1.28B
-3.63%-4.39%-38.58%-38.65% 1.18B
+1.85%+18.34%-36.23% - 1.13B
-0.03%+0.67%+25.70%+83.65% 1.12B
-5.87%-12.79%+38.97%+125.72% 571M
-0.41%-11.66%+55.78% - 308M
+1.91%+1.12%-61.54%+288.80% 258M
Average -1.38%-2.78%-5.27%+54.86% 2.38B
Weighted average by Cap. -1.34%-2.00%-7.84%-1.93%

Financials

2024 2025
Net sales 588K 504K 471K 432K 812K 56.15M 825K 5.55M 2.17M 28.16M 2.21M 2.16M 93.12M 461K 396K 370K 339K 638K 44.11M 648K 4.36M 1.71M 22.12M 1.73M 1.69M 73.14M
Net income -2.38M -2.04M -1.91M -1.75M -3.29M -227M -3.34M -22.49M -8.81M -114M -8.93M -8.74M -377M -10.6M -9.1M -8.49M -7.79M -14.65M -1.01B -14.89M -100M -39.24M -508M -39.81M -38.95M -1.68B
Net Debt 1.42M 1.22M 1.14M 1.05M 1.97M 136M 2M 13.46M 5.27M 68.28M 5.35M 5.23M 226M -1.14M -975K -910K -835K -1.57M -109M -1.6M -10.74M -4.2M -54.46M -4.27M -4.17M -180M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
19/08/26 $1.780 -1.66% 3,732
18/08/26 $1.810 +5.23% 3,600
17/08/26 $1.720 -4.99% 3,446
14/08/26 $1.810 +4.04% 6,600
13/08/26 $1.740 -3.87% 39,687
  1. Stock Market
  2. Stocks
  3. POSC Stock